TFIID and MYB Share a Therapeutic Handshake in AML.

Bell, Charles C; Dawson, Mark A

Bell, Charles C; Dawson, Mark A.

Afiliação

Bell CC; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3052, Australia.
Dawson MA; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3052, Australia; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. Electronic address: mark.dawson@petermac.org.

Cancer Cell ; 33(1): 1-3, 2018 01 08.

Article em En | MEDLINE | ID: mdl-29316424

ABSTRACT

ABSTRACT

Selectively disrupting oncogenic transcription factors in cancer remains an elusive ambition of targeted therapeutics. In this issue of Cancer Cell, Xu et al. provide an elegant proof-of-concept study demonstrating that interaction between MYB and the general transcriptional coactivator TFIID can be specifically disrupted to mediate a therapeutic effect in AML.

Assuntos

Fator de Transcrição TFIID/genética; Fatores de Transcrição; Humanos; Leucemia Mieloide Aguda; Transcrição Gênica

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Fator de Transcrição TFIID Limite: Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google